Safety Shot Gets 180-Day Window to Restore Nasdaq Compliance on Stock Price Front

Wellness supplement maker Safety Shot, Inc. (Nasdaq: SHOT) has secured an extension from The Nasdaq Stock Market that extends its compliance deadline to December 29, 2025, according to a notice issued by the exchange’s Listing Qualifications Staff on July 16, 2025.

The extension addresses the Company’s struggle with maintaining the minimum bid price threshold on the Nasdaq Capital Market. Safety Shot currently meets all other listing standards for the exchange, but fell short on the bid price metric. The newly granted 180-calendar day period provides additional runway to resolve this deficiency.

The Path Forward for Compliance

For Safety Shot to regain compliance, its common stock (trading under ticker SHOT) must maintain a closing bid price of at least $1.00 per share for a consecutive 10 business-day period before the December deadline arrives. The Company’s listing status remains unchanged during this compliance window, and shares will continue trading on the Nasdaq Capital Market as normal.

CEO Jarrett Boon expressed confidence in the timeline, stating that the Board has already evaluated multiple strategic pathways to meet the price requirement. “The extension gives us the breathing room we need while we stay focused on our core operations and the Yerbaé integration,” Boon remarked.

Consequences of Non-Compliance

Should Safety Shot fail to meet the minimum bid price requirement by the December 29 deadline, Nasdaq will formally notify the Company of potential delisting. At that juncture, Safety Shot would have the option to challenge the delisting determination before a Nasdaq Hearings Panel.

About the Company

Safety Shot develops and markets Sure Shot, a patented dietary supplement engineered to reduce blood alcohol content while enhancing mental clarity and energy. The product is currently distributed through major retail channels including online platforms and brick-and-mortar locations.